Leukemia

In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.

CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab.

Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show.

A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.

Venetoclax had promising clinical activity in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with idelalisib.

Two years of maintenance chemotherapy with rituximab resulted in improved progression-free survival among elderly patients with chronic lymphocytic leukemia.

In this interview, we discuss the results of the phase III MURANO trial, which tested the combination of venetoclax with rituximab in relapsed/refractory CLL.

Presence of germline TP53 variants predisposed children to acute lymphoblastic leukemia and was associated with adverse outcomes compared with children who did not have these variants, according to the results of a new study.

Duvelisib improved the median progression-free survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma by about 3.5 months compared with the current standard, ofatumumab.

Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the phase III RELEVANCE trial.

BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.

Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.

Venetoclax has durable clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.

The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.

The FDA approved bosutinib (Bosulif) for use as a treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia.

Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.

In this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and radioiodine therapy vs those treated with surgery alone.

A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study.

Data presented at the 2017 ASH meeting showed that copanlisib resulted in an improved response rate and low rate of severe toxicities in patients with relapsed/refractory B-cell lymphomas.

A combination of ibrutinib plus standard chemoimmunotherapy induces deep responses in a relatively high-risk group of previously untreated, young chronic lymphocytic leukemia patients, according to a new study.

Adding rituximab to MBVP induction chemotherapy does not improve outcomes for patients with primary central nervous system lymphoma.

This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.

A study presented at the 2017 ASH annual meeting showed that mogamulizumab resulted in significantly superior progression free survival and better outcomes compared with vorinostat in patients with previously treated CTCL.

A proof-of-concept study has demonstrated that resistance to treatment in multiple myeloma and mantle cell lymphoma could be linked to a protein called Nrf1, which appears to respond to proteasome insufficiency or pharmacological inhibition.